Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 220-228

  Kalonia, Harikesh ^a   Kumar, Puneet ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Huntington; Mitochondrial dysfunction; Neurotoxicity; Oxidative stress; Statins

Indexed keywords

ATORVASTATIN; CATALASE; FLUINDOSTATIN; NITRITE; QUINOLINIC ACID; SIMVASTATIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; HUNTINGTON DISEASE LIKE SYNDROME; LIPID PEROXIDATION; LOCOMOTION; MALE; MORNING DOSAGE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; CORPUS STRIATUM; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPID PEROXIDATION; MALE; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NITRITES; OXIDATIVE STRESS; PYRROLES; QUINOLINIC ACID; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SIMVASTATIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149408231     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.07.040     Document Type: Article

References (69)

1. Amori L., Wu H.Q., Marinozzi M., Pellicciari R., Guidetti P., Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 2009, 159:196-203.
2. Araujo D.M., Cherry S.R., Tatsukawa K.J., Toyokuni T., Kornblum H.I. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Exp Neurol 2000, 166:287-297.
3. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999, 73:1127-1137.
4. Bösel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P.C., et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005, 92:1386-1398.
5. Braidy N., Grant R., Adams S., Brew B.J., Guillemin G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009, 16:77-86.
6. Butterick T.A., Igbavboa U., Eckert G.P., Sun G.Y., Weisman G.A., Müller W.E., et al. Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Mol Neurobiol 2010, 41:384-391.
7. Cimino M., Gelosa P., Gianella A., Nobili E., Tremoli E., Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007, 13:208-213.
8. Cordle A., Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005, 25:299-307.
9. Crisby M. The role of pleiotropic effects of statins in dementia. Acta Neurol Scand Suppl 2006, 185:115-118.
10. DeAngelis T., Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J Med 2008, 75:157-167.
11. Dong X.X., Wang Y., Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009, 30:379-387.
12. Eckert G.P., Hooff G.P., Strandjord D.M., Igbavboa U., Volmer D.A., Müller W.E., et al. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 2009, 35:251-257.
13. Estrada Sánchez A.M., Mejía-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008, 39:265-276.
14. Franke C., Noldner M., Abdel-Kader R., Johnson-Anuna L.N., Gibson Wood W., Muller W.E., et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 2007, 25:438-445.
15. Ganzella M., Jardim F.M., Boeck C.R., Vendite D. Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neurosci Res 2006, 55:397-402.
16. Gil J.M., Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008, 27:2803-2820.
17. Ginter E., Simko V. Statins: the drugs for the 21st century?. Bratisl Lek Listy 2009, 110:664-668.
18. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949, 177:751-766.
19. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannebaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann Biochem 1982, 126:131-138.
20. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
21. Johnson-Anuna L.N., Eckert G.P., Franke C., Igbavboa U., Muller W.E., Wood W.G. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem 2007, 101:77-86.
22. Johnson-Anuna L.N., Eckert G.P., Keller J.H., Igbavboa U., Franke C., Fechner T., et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005 Feb, 312(2):786-793.
23. Kalonia H., Kumar P., Kumar A., Nehru B. Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacology 2009, 17:211-219.
24. Kalonia H., Kumar P., Kumar A., Nehru B. Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. Neurotoxicology 2010, 31:195-203.
25. Kim J.H., Kim S., Yoon I.S., Lee J.H., Jang B.J., Jeong S.M., et al. Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005, 48:743-756.
26. King T.E., Howard R.L. Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 1967, 10:275-284.
27. King T.E. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol 1967, 10:322-331.
28. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 1978, 186:189-195.
29. Kulkarni S.K. Hand book of experimental pharmacology 1999, Vallabh Prakashan, Delhi. 3rd ed.
30. Leblhuber F., Walli J., Jellinger K., Tilz G.P., Widner B., Laccone F., et al. Activated immune system in patients with Huntington's disease. Clin Chem Lab Med 1998, 36:747-750.
31. Leonhardt W., Kurktschiev T., Meissner D., Lattke P., Abletshauser C., Weidinger G., et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol 1997, 53:65-69.
32. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628.
33. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007, 69:878-885.
34. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., et al. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008, 283:5780-5789.
35. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem 1997, 69:581-593.
36. Luck H. Catalase. Methods of enzymatic analysis 1971, 885-893. Academic Press, New York. H.U. Bergmeyer (Ed.).
37. Maragos W.F., Jakel R.J., Pang Z., Geddes J.W. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp Neurol 1998, 154:637-644.
38. Markovic-Plese S., Singh A.K., Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol 2008, 3:153-167.
39. Mason R.P. A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord 2005 Dec, 5(6):489-501.
40. Miida T., Takahashi A., Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther 2007, 113:378-393.
41. Milakovic T., Quintanilla R.A., Johnson G.V. Mutant Huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem 2006, 281:34785-34795.
42. Nicholls D.G., Budd S.L., Ward M.W., Castilho R.F. Excitotoxicity and mitochondria. Biochem Soc Symp 1999, 66:55-67.
43. Obata T. Protective effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on copper-induced hydroxyl radical generation in the rat heart. Toxicology 2006, 223:175-180.
44. Ong W.Y., Kim J.H., He X., Chen P., Farooqui A.A., Jenner A.M. Changes in brain cholesterol metabolome after excitotoxicity. Mol Neurobiol 2010, 41:299-313.
45. Orr J.D. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep 2008, 10:11-18.
46. Palaniswamy C., Selvaraj D.R., Selvaraj T., Sukhija R. Mechanisms underlying pleiotropic effects of statins. Am J Ther 2010, 17:75-78.
47. Patassini S., Giampà C., Martorana A., Bernardi G., Fusco F.R. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett 2008, 448:166-169.
48. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, San Diego, p-256. 6th ed.
49. Peng T.I., Greenamyre J.T. Privileged access to mitochondria of calcium influx through N-methyl-d-aspartate receptors. Mol Pharmacol 1998, 53:974-980.
50. Pezzini A., Del Zotto E., Volonghi I., Giossi A., Costa P., Padovani A. New insights into the pleiotropic effects of statins for stroke prevention. Mini Rev Med Chem 2009, 9:794-804.
51. Pienaar I.S., Schallert T., Hattingh S., Daniels W.M. Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration. J Neural Transm 2009, 116:791-806.
52. Rossato J.I., Zeni G., Mello C.F., Rubin M.A., Rocha J.B. Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat. Neurosci Lett 2002, 318:137-140.
53. Rothman S.M. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J Neurosci 1985, 5:1483-1489.
54. Salat D., Ribosa R., Garcia-Bonilla L., Montaner J. Statin use before and after acute ischemic stroke onset improves neurological outcome. Expert Rev Cardiovasc Ther 2009, 7:1219-1230.
55. Santamaría A., Ríos C. MK-801, an N-methyl-d-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci Lett 1993, 159:51-54.
56. Schanne F.A., Kane A.B., Young E.E., Farber J.L. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.
57. Schwarcz R., Foster A.C., French E.D., Whetsell W.O., Kohler C. Excitotoxic models for neurodegenerative disorders. Life Sci 1984, 35:19-32.
58. Sottocasa G.L., Kuylenstierna B., Ernster L., Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 1967, 32:415-438.
59. Stoll L.L., McCormick M.L., Denning G.M., Weintraub N.L. Antioxidant effects of statins. Drugs Today (Barc) 2004, 40:975-990.
60. Tahara N., Kai H., Ishibashi M., Nakaura H., Kaida H., Baba K., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
61. Tong X.K., Nicolakakis N., Fernandes P., Ongali B., Brouillette J., Quirion R., et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 2009, 35:406-414.
62. Tzeng S.F., Hsiao H.Y., Mak O.T. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:335-340.
63. Valenza M., Carroll J.B., Leoni V., Bertram L.N., Björkhem I., Singaraja R.R., et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by Huntingtin mutation. Hum Mol Genet 2007, 16:2187-2198.
64. van der Most P.J., Dolga A.M., Nijholt I.M., Luiten P.G., Eisel U.L. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009, 88:64-75.
65. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003, 100:10483-10487.
66. Wang X.M., Gao X., Zhang X.H., Tu Y.Y., Jin M.L., Zhao G.P., et al. The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning. Biochem Biophy Res Commun 2006, 340:1023-1027.
67. Wills E.D. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966, 99:667-676.
68. Wojda U., Salinska E., Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life 2008, 60:575-590.
69. Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003, 23:11104-11111.